A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation

Non Small Cell Lung Clinical Trial

Official title:
A Phase 2 Clinica Study: Efficacy and Safety of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation

Status Recruiting

Clinical Trial Summary

This study is designed to evaluate the efficacy and safety of Pyrotinib in patients of advanced pre-treated Non-small cell lung cancer With HER2 Mutation.

To observe objective response rate (ORR) of pyrotinib in NSCLC With HER2 Mutation. To observe Progression free survival (PFS). To assess the overall survival (OS).

A secondary aim is to obtain safety information.

To explore the relationship between biomarkers and the toxicity/efficacy of Pyrotinib.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02834936
Study type	Interventional
Source	Jiangsu HengRui Medicine Co., Ltd.
Contact
Status	Recruiting
Phase	Phase 2
Start date	September 27, 2016
Completion date	June 2018

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00532155` - A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer	Phase 3
	Completed	`NCT00577746` - Clinical Impact of EUS in Staging NSCLC	N/A